Ames IA 肺癌临床试验
7项针对 肺癌的研究正在 Ames及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
招募中3 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
招募中3 期
- McFarland Clinic, Ames
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
招募中3 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
其他城市的 肺癌试验
- Houston, TX78 项研究
- Boston, MA62 项研究
- New York City, NY60 项研究
- Los Angeles, CA45 项研究
- Washington, DC41 项研究
- Arlington, VA41 项研究
- Chicago, IL41 项研究
- Nashville, TN40 项研究
- Baltimore, MD40 项研究
- St. Louis, MO39 项研究
- Columbus, OH37 项研究
- Philadelphia, PA36 项研究
Ames的其他研究
- 前列腺癌7 项研究
- 非小细胞肺癌6 项研究
- 肾癌（肾细胞癌）5 项研究
- 头颈鳞状细胞癌4 项研究
- 乳腺癌4 项研究
- 膀胱癌4 项研究
- 黑色素瘤3 项研究
- 下咽癌3 项研究
- 喉癌3 项研究
- 口腔癌3 项研究
- 慢性淋巴细胞白血病3 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。